HARTIS Pharma

Hartis Pharma is a French specialty pharmaceutical company headquartered in Saint-Priest, specializing in the development and commercialization of "hybrid" medicines. Founded in 2014, the company focuses on therapeutic areas including oncology, hematology, and supportive care, aiming to improve existing treatments through innovative formulations or new indications. Hartis Pharma maintains a strategic partnership with Zydus Lifesciences to market the Zituvio (sitagliptin) and Zituvimet (sitagliptin + metformin) range for type 2 diabetes in the French market. Additionally, the company is advancing its own R&D pipeline, notably the HP-01 program for the prevention and treatment of oral mucositis in cancer patients. The firm's business model leverages both the distribution of established specialty products and the internal development of value-added therapies to address unmet medical needs.